Pfizer Raises 2026 Revenue Guidance by $500 Million Amid Strong Q2 Results
Pfizer reported a 3% increase in Q2 2026 revenues, raising its full-year revenue guidance by $500 million due to strong performance in non-COVID products.
Asset / Drug
Drug and asset intelligence for Eliquis with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.